Evidence map›Paper›PMID 35178043›Full record

ArticleFrontiers in microbiology2022

Antibacterial Activity of Small Molecules Which Eradicate Methicillin-Resistant

Mohamad Hamad, Farah Al-Marzooq, Vunnam Srinivasulu, Hany A Omar, Ashna Sulaiman, Dana M Zaher, Gorka Orive, Taleb H Al-Tel

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Deciphering the genetic context of the emerging OXA-484-producing carbapenem-resistant Escherichia coli from ST167 high-risk clone in the United Arab Emirates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  4. Article
  5. Article
  6. Tea Tree Essential Oil KillsBiomolecules · 2023
    Article
  7. Review
  8. Boosting the Antibacterial Activity of Azithromycin on Multidrug-ResistantInternational journal of molecular sciences · 2023
    Article
  9. Article
  10. Antibiotics (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Mohamad HamadSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Farah Al-MarzooqSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Vunnam SrinivasuluSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Hany A OmarSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Ashna SulaimanSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Dana M ZaherSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Gorka OriveNanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Bilbao, Spain.
Taleb H Al-TelSharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
University of Sharjah · AEUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The serious challenge posed by multidrug-resistant bacterial infections with concomitant treatment failure and high mortality rates presents an urgent threat to the global health. We herein report the discovery of a new class of potent antimicrobial compounds that are highly effective against Gram-positive bacteria, including methicillin-resistant

Indexed as

antibacterialbacterial resistanceMRSAmulti-drug resistancepersistersStaphylococcus aureus

Identifiers

PMID35178043
PMCPMC8846302
OpenAlexW4213246830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.